RG

Rahul Gawande Sudhakar

Active Director Director DIN 07477010
DIN 07477010 First appointment Jul 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 1 historical roles
Total affiliations 4 Since Jul 2016
Shareholding value •••• Premium profile

About Rahul Gawande Sudhakar

Data last updated:

Rahul Gawande Sudhakar is a Director at Orbicular Pharmaceutical Technologies Private Limited (since 2019), Director at Invitron Advanced Analytics Private Limited (since 2022) and Director at Revitos Specialities Private Limited (since 2020). The companies operate in Pharma and FMCG. The 2 current companies with reported revenue have a combined latest revenue of ₹315 Cr; the largest is Orbicular Pharmaceutical Technologies Private Limited at ₹272 Cr (FY 2025). Earlier, Rahul Gawande Sudhakar was a Director at Aleor Dermaceuticals Limited (2016–2022).

DIN 07477010
Primary Designation Director
Industry Pharma
First Appointment 18 Jul 2016
Oldest Company Age 18 yrs
Largest company Orbicular Pharmaceutical Technologies Private Limited · ₹272 Cr (FY 2025)
Combined revenue ₹315 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Jul 20192008₹272 Cr (FY 2025)Active
Director11 Oct 20222013₹43.23 Cr (FY 2025)Active
Revitos Specialities Private Limited U24290TG2017PTC120067
Director01 Oct 20202017Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aleor Dermaceuticals Limited U24302GJ2016PLC092131
Director18 Jul 20162016₹16.23 Cr (FY 2021)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Orbicular Pharmaceutical Technologies Private Limited
Revitos Specialities Private Limited
Invitron Advanced Analytics Private Limited
Aleor Dermaceuticals Limited
Premium access

Shareholding and investment profile for Rahul Gawande Sudhakar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Gawande Sudhakar

Rahul Gawande Sudhakar currently holds 3 directorships: Orbicular Pharmaceutical Technologies Private Limited (Director, since 01 Jul 2019, revenue ₹272 Cr (FY 2025)); Invitron Advanced Analytics Private Limited (Director, since 11 Oct 2022, revenue ₹43.23 Cr (FY 2025)); Revitos Specialities Private Limited (Director, since 01 Oct 2020).

Rahul Gawande Sudhakar was first appointed on 18 Jul 2016 as Director at Aleor Dermaceuticals Limited. The most recent appointment on record is 11 Oct 2022 at Invitron Advanced Analytics Private Limited.

The 2 current companies of Rahul Gawande Sudhakar that report revenue have a combined latest revenue of ₹315 Cr: Orbicular Pharmaceutical Technologies Private Limited ₹272 Cr (FY 2025); Invitron Advanced Analytics Private Limited ₹43.23 Cr (FY 2025).

Rahul Gawande Sudhakar held 1 earlier board appointment: Aleor Dermaceuticals Limited (Director, 18 Jul 2016 to 28 Mar 2022).

The current boards of Rahul Gawande Sudhakar's companies include Balaji Boggarapu (Orbicular Pharmaceutical Technologies Private Limited), Bhaveshkumar Vallabhbhai Patel (Orbicular Pharmaceutical Technologies Private Limited), Hiren Dasharathbhai Patel (Orbicular Pharmaceutical Technologies Private Limited), Meena Mohan (Orbicular Pharmaceutical Technologies Private Limited), Sivaraman Mohan Mailatur (Orbicular Pharmaceutical Technologies Private Limited), Visalakshi Chandramouli (Orbicular Pharmaceutical Technologies Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available